Eli Lilly’s weight-loss and diabetes drugs are already driving unusually fast growth, but the bigger twist is a next‑generation treatment still in late-stage testing that could expand the company’s reach if results hold up. The upside comes with real pressure from price cuts, tougher reimbursement rules, and the risk that future trial readouts disappoint.Read more